led to strategies to deplete the tumor cells from the harvest product prior to reinfusion of the stem cells. One of the current attempts at purifying the harvest proMonoclonal plasma cells (CD38 + CD45 − /dim) are typically present in the blood of patients with active myeduct uses antibody to the CD34 antigen to positively select and enrich hematopoietic stem cells and in the process loma and can contaminate stem cell harvests. This has led to strategies that select CD34
The CD34 antigen identifies a lymphohematopoietic stem logous stem cell transplantation with the goal of decreasing tumor cell contamination. The aim of this cell, is present on 1-5% of adult bone marrow cells, and is expressed on early B cells. The characteristics of this study was to learn if the CD34 antigen is expressed on monoclonal plasma cells in the blood or marrow of important antigen and its clinical relevance have recently been reviewed. 14 CD34 + hematopoietic cells from blood or patients with multiple myeloma. We used three-color flow cytometry (surface CD38;CD45 and cytoplasmic marrow can reconstitute hematopoiesis after high-dose therapy programs. 15 The number of CD34 + cells reinfused kappa or lambda) to identify monoclonal plasma cells in the blood (n = 24) and marrow (n = 37) from patients predicts the time to engraftment. 16, 17 If stem cells are to be selected on the basis of their with plasma cell proliferative disorders. In each case the CD38 + CD45 − and CD38 + CD45 dim+ monoclonal popuexpression of CD34 for use in transplants for multiple myeloma, it is important to demonstrate that the CD34 antilations were then analyzed for CD34 expression. In all 24 blood and 37 marrow samples, the CD38
+

CD45
− gen is not on the myeloma cells. There are two methods to approach this question. The first involves isolating cells monoclonal plasma cells were negative for CD34 expression. CD38
+
CD45
dim+ monoclonal cells were docuwith CD34 antibody followed by analysis of this cell population for myeloma cells by use of molecular techmented in the blood of 11 patients and in the marrow of 33 patients and this cell population was also CD34-niques. 9, 13, 18, 19 The aim of this study was to address the question with a second approach that identified the known negative in all cases. These results indicate that CD34 is usually not expressed on the CD38 + CD45 − CD45 dim+ myeloma cells by three-color flow cytometry to learn if the CD38 + CD45 − CD45 dim+ monoclonal plasma cell population monoclonal plasma cells in the blood or marrow of patients with plasma cell proliferative disorders. CD34 in the blood or marrow from patients with plasma cell proliferative diseases expressed the CD34 antigen. selection methods should therefore decrease the chance of tumor cell contamination of the stem cell product. Keywords: CD34; multiple myeloma; stem cell transplants
Materials and methods
Patient selection Multiple myeloma is a malignancy of monoclonal plasma
All patients had the diagnosis of a plasma cell proliferative cells that are found in highest number in the bone marrow.
disorder and were seen in the Dysproteinemia Clinic, Mayo Malignant cells can also circulate in the blood of patients Clinic, Rochester in 1995. Since the sole purpose of the especially those with active disease. [1] [2] [3] Current therapeutic study was to examine the expression of CD34 on the blood approaches utilize autologous stem cells to replenish the and marrow tumor cells from patients with a plasma cell marrow of patients treated with high-dose therapy proliferative disorder, the only eligibility criteria were a programs. Several groups have documented that clonal documented plasma cell proliferative disorder and the presmyeloma cells can contaminate the blood stem cell harvest ence of monoclonal plasma cells detected in a sample of products from patients with multiple myeloma. [4] [5] [6] [7] [8] [9] [10] 
CD45
− cells The addition of a third marker to detect cytoplasmic light detected and in 46% (11/24) we were able to establish by chain restriction further confirms the clonality of the plasma this technique that there were monoclonal cells in the cells. 23 For this study, blood and marrow monoclonal CD45 dim+ population. CD34 expression was not detected on plasma cells were identified by three-color flow cytometry the CD38 + CD45 − population in all 24 cases nor in the 11 as previously described. 23 Briefly, blood monoclonal cases with a CD38 + CD45 dim+ monoclonal cell population. plasma cells were identified in lysed whole blood speciWe also evaluated the expression of CD34 on the mens in which red blood cells were lysed with ammonium CD38 + CD45 dim+ cells that were found to be polyclonal in chloride or in mononuclear cells isolated on Ficollthe analysis of cytoplasmic kappa and lambda in the other Hypaque from heparinized blood. The cells to be analyzed 13 cases and they were also negative for CD34 expression. for surface CD38/CD45 and cytoplasmic kappa or lambda were incubated with phycoerythrin (PE)-conjugated antihuman CD38 (Becton Dickinson, Mountain View, CA, CD34 expression on bone marrow myeloma cells USA) and PerCP-conjugated anti-human CD45 for 15 min;
The bone marrow from 37 patients were studied and 100% then washed, fixed with 4 ml of lysolecithin solution and had a population of monoclonal CD38 + CD45
− or incubated for 30 min at 4°C in the dark. After washing with CD38 + CD45 dim+ cells detected in the marrow. Twenty-five 3 ml of PBS/3% BSA the pellet was resuspended in 200 of these patients had active multiple myeloma (15 new mull PBS/BSA and 100 l added to each of two 12 × 75 tiple myeloma; 10 relapsed) requiring treatment and 12 had tubes. To these tubes was added either FITC conjugated inactive disease (two with stable disease after chemoanti-human kappa or lambda light chain antibody (Tago, therapy; four with indolent or SMM; and six with MGUS). Amarillo, CA, USA) and the suspension incubated for 30
All 37 patients had monoclonal CD38 + CD45 − cells min in the dark at 4°C. After incubation, the cells were detected and CD34 was not expressed on this cell popuwashed with 2 ml PBS, resuspended in 0.5 ml 1% paraforlation in any of the cases. In 89% (33/37) of the cases maldehyde, and analyzed on a FACScan flow cytometer. monoclonal cells were documented in the CD45 dim+ popuGates were set around the CD38 +
− and the lation and, again the CD34 antigen was not found to be CD38 +
dim+ quadrant and the percentage of the cells expressed on this cell population in any of theses cases expressing kappa and lambda were compared to determine (Figure 1 ). We also evaluated the expression of CD34 on monoclonality. CD45 dim+ cells were those that occupied the the CD38 + CD45 dim+ cells that were found to be polyclonal gated region between the cells in the sample that did not in the analysis of cytoplasmic kappa and lambda and they stain for CD38 or CD45 and the normal lymphocytes with were also negative for CD34 antigen expression. their characteristic strong CD45 expression. Monoclonal kappa was defined as a kappa:lambda ratio у5; monoclonal lambda as a kappa:lambda ratio р0. 5 patients eventually relapse after this therapy, attention needs to be focused on providing a stem cell product free of myeloma cells, improving the preparative regimens, and providing therapy in the post-transplant period that can Results maintain the response. The finding that the stem cell harvest products are often Patient characteristics contaminated with myeloma cells has led to strategies to improve the quality and purity of the stem cells. These straThe blood or marrow used for this study came from 38 patients with a documented plasma cell proliferative distegies include collection of blood stem cells during the response phase of disease when circulating tumor cells are order. Both blood and marrow were utilized from 23 patients; marrow alone in 14; and blood only in one. Six lower than at the time of diagnosis or relapse 29 and prior to significant exposure to alkylating agents that may otherwise patients had a monoclonal gammopathy of undetermined significance (MGUS); four had indolent or smoldering mulimpair engraftment of the stem cells. Purging by positive selection of CD34 + stem cells has been shown to enrich the tiple myeloma (SMM); 15 had new multiple myeloma; two had stable disease after chemotherapy; and 11 had relapsed stem cell product for CD34 + cells 12 and reduce the contaminating tumor cells 9,13,18 without affecting engraftment. multiple myeloma.
five patients no myeloma clonal sequences were detected. This same group used this technique to analyze myeloma cell contamination of the blood stem cell product in 14 patients before and after CD34 selection. Tumor was detected in eight of 14 before and in only three after CD34 selection. 13 Gazitt et al 9 studied mobilized blood stem cell harvests before and after a purification procedure that used counterflow elutriation centrifugation, treatment with phenylalanine methylester and flow sorting. They demonstrated that this procedure led to an approximately 50-fold enrichment in stem cells and a depletion of tumor cells in the CD34 + Lin − Thy + population. Takashita et al 19 used flow cytometry to sort blood lymphocytes from three patients into a CD34 + population. Clonal sequences were found in this CD34
+ cell population by use of clone-specific probes made from the myeloma cells. CD34
+ cells from the bone marrow were not tested. These results are at odds with the results of the other published investigations 9, 13, 18 and need to be confirmed on a larger number of patients. One potential explanation is that because a large number of cells (up to 10 6 ) were sorted to obtain the CD34 + population, it is possible that some CD34
− cells that were part of the myeloma clone may have been included and subsequently amplified by PCR thereby influencing the final results.
Our study investigated whether myeloma cells identified by three-color flow cytometry express the CD34 antigen. We identified these cells by their characteristic CD38 +
− CD45 dim+ monoclonal cytoplasmic light chain immunophenotype. By this method we were able to study samples of blood and marrow that contained myeloma cells from a large number of patients and demonstrate that the CD34 antigen is not expressed on these cells. It is possible that there are cells that are part of the myeloma clone that could have been CD34
+ that were not identified by gating on CD38 + CD45 − CD45 dim+ cells. However, our results are consistent with the studies cited above that show that the clonal myeloma cells are not in the CD34
+ popu- 14 there has been concern that procedures that progression after autologous blood stem cell transplants and a shorter overall survival. 30 Studies of genetically marked select CD34
+ cells for use in transplantation of patients with multiple myeloma may, in addition to enriching for stem stem cells harvested from the blood have documented that they can restore hematopoietic function when reinfused; cells, also include myeloma cells. Three studies using molecular techniques have shown that the enriched CD34 + cell however, it has not yet been shown that the infused myeloma cells are responsible for relapse after blood stem cell population is devoid or depleted of myeloma tumor cells. Vescio et al 18 obtained marrow myeloma cells from five transplants. 31 As the preparative regimens and post-transplant therapy improve, it will become more important to patients and developed a unique, patient-specific oligonucleotide primer based on the complementarity determining provide a stem cell product free of myeloma cells. region of each myeloma immunoglobulin sequence. The CD34 + cells were isolated from the same marrow sample Acknowledgements by an immunoadsorption column and flow cytometry sorting. The patient-specific oligonucleotide was then used to This work was supported in part by grant number CA62242 from the National Cancer Institute (National Institutes of Health).
amplify the DNA from the CD34-selected cells and in all stem cells (PBSCs) collected after recombinant granulocyte
